Preclinical News and Research

RSS

Potential treatment for multiple sclerosis goes to trial

A potential treatment for multiple sclerosis (MS), developed by University of Greenwich in association with Kings College, London, has begun clinical trials.

15 Apr 2008

NovoCure presents results from breast cancer pilot study

NovoCure announced today that it presented the results from a single-arm pilot trial evaluating the Novo-TTF, a non-invasive portable medical device, combined with neo-adjuvant chemotherapy for the treatment of patients with locally advanced breast cancer.

15 Apr 2008

Potential new therapy for myeloproliferative disorders

A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia.

8 Apr 2008

Skin product decreases malignant melanoma tumor growth according to study

A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

8 Apr 2008

NanoViricides begins HIV drug animal trials

NanoViricides, Inc. has announced that preliminary animal trials of the Company's HIV therapeutic candidates have begun at a BioSafety Level 3 (BSL-3) Laboratory facility in Boston, MA.

8 Apr 2008

Special journal section explores geriatric assessment

The latest issue of The Journal of Gerontology: Medical Sciences (Vol. 63, No. 3) features a special section devoted to the phenomenon of multidimensional geriatric assessment - an interdisciplinary diagnostic process to determine the medical, psychological, and functional status of at-risk and frail elderly patients in order to develop a coordinated, integrated plan for treatment and long-term follow-up.

7 Apr 2008

FDA approves TREANDA (bendamustine hydrochloride) for chronic lymphocytic leukemia

Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.

7 Apr 2008

Clinical trial to test a novel HIV/AIDS vaccine

This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

4 Apr 2008

Disappointing resuts for pimecrolimus, investigational anti-restenosis drug

A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

1 Apr 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

25 Mar 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008

NanoBio completes interim analysis of phase 2 clinical trial in onychomycosis

NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists

24 Mar 2008

EpiCept announces opinion by European Regulatory Authority on Ceplene

EpiCept Corporation has announced that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued, as expected following the trend vote announced last month, a negative opinion regarding the marketing authorization application (MAA) for Ceplene (histamine dihydrochloride) for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission.

24 Mar 2008

Russell Berrie Foundation donates $28 million for diabetes research

The Russell Berrie Foundation has donated $28 million to Columbia University Medical Center and NewYork-Presbyterian Hospital, as part of a focused effort to provide comprehensive care to diabetes patients while working, through concentrated research initiatives, toward a cure, the Medical Center gratefully announced today.

20 Mar 2008

MedImmune advances clinical development of antibody targeting interleukin-9 in patients with asthma

MedImmune has announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma.

19 Mar 2008

Compound found in soybeans may halt spread of prostate cancer

A compound found in soybeans almost completely prevented the spread of human prostate cancer in mice, according to a study published in the March 15 issue of Cancer Research, a journal of the American Association for Cancer Research.

17 Mar 2008

Lilly and Transition Therapeutics announce licensing and collaboration agreement

Eli Lilly and Company and Transition Therapeutics Inc. has announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.

14 Mar 2008

Novel brain cancer drug HhAntag for children may damage bones

A novel drug that fully eliminated brain tumors from mice in a dramatic 2004 study has shown a darker side - causing permanent bone damage in younger mice.

11 Mar 2008

Tackling antimicrobial resistance

Drug resistance is making many diseases increasingly difficult and sometimes impossible to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

11 Mar 2008